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Paul Linde:  As a clinician, one message I
take away from the imaging information is
that methamphetamine and cocaine cause
frontal lobe dysfunction, resulting in dam-
age to decisionmaking, judgment, and impulse
control. All of these play a role in relapse as
well. We can educate people about this and
about staying abstinent to try to protect their
brains from further injury.
Linda Chang:  Not only protect the brain
from further injury, but also give it time
to heal. We don’t know how much of the
damage drugs do is permanent. For exam-
ple, in the past, we assumed that when
you see a decreased dopamine transporter
density on the PET scan, those dopamine
neurons are permanently impaired or gone.
But Nora Volkow and I found that after a
group of methamphetamine abusers were
abstinent for a long period—more than 6
or 12 months—their dopamine transporter
levels started to improve. This suggests that
if you stop using the drug for long enough,
the brain cells can actually recover. Gene-
Jack Wang also published a PET study that
found more normal brain function in for-
mer methamphetamine abusers who had
been abstinent for a long time than in those
who were still in early abstinence (Wang
et al., 2004).
Even when there is permanent damage,
the brain may find ways to compensate.
In fact, this happens in all forms of brain
injury. My colleagues and I have done func-
tional MRIs in patients with HIV-related
brain injury and observed that when one
part is not working well, the brain uses its
reserves or other parts to maintain its func-
tion. It’s only when the reserve capacity is
exhausted that they then develop cognitive
deficits or impairments.
There is an emerging literature showing
that cognitive-behavioral therapy may reroute
brain function to maintain or restore lost
capacity. Patients who have decisionmak-
ing or impulse control or other problems
may learn to tap into parts of the brain they
haven’t used in the past.
Linde: Among my patients, who are mainly
recovering methamphetamine and cocaine
abusers, the cognitive and motor issues seem
minor compared with mood problems. There
also is a clear subset of patients who essen-
tially develop low-grade schizophrenia after
prolonged methamphetamine abuse, par-
ticularly those who have taken the drug intra-
venously for a year or longer. Unfortunately,
one man I was seeing still had a psychotic
disorder after 18 months of abstinence. It
was a low-grade paranoid delusional disor-
der with occasional hallucinations. Can
imaging help with this?
Chang: I don’t know of anyone who has
really focused on those patients. It would
be very interesting to do imaging studies in
the subpopulation of individuals who don’t
show significant recovery, to see if their brains
look different. Either they are predisposed
to psychosis, or their damage was more 
severe.
Imaging and medications
Linde: Many of the methamphetamine
abusers we see relapse to escape their with-
drawal symptoms, particularly the long-
term anhedonia and hypersomnia, fatigue,
and low energy. Does the brain of someone
who is a chronic methamphetamine abuser
look anything like the brain of someone who
has depression or atypical depression? 
Chang: I haven’t imaged the depressed pop-
ulation myself, but, based on the literature,
the answer is no. When Nora Volkow, Joanna
Fowler, and I imaged methamphetamine
abusers, we saw decreased dopamine recep-
tors and transporters and abnormal glucose
uptake, concentrated in the orbitofrontal
and the parietal regions. Those are not the
same abnormalities reported in depressed
individuals, which are more in the dorsal
frontal areas and usually unilateral on the
right side.
Edythe London and colleagues addressed
this issue directly in a PET study she pub-
lished a couple of years ago in the Archives
of General Psychiatry.She specifically looked
at changes in brain metabolism within the
first 4 to 7 days of stopping methamphet-
amine—the period of super acute with-
drawal. She found that the more depressed
these patients were, the higher the metab-
olism was in their cingulate area (London
et al., 2004). So methamphetamine abusers
have brain abnormalities that correlate with
their depression, but they aren’t the same
ones we see in depressed non-drug-abusers.
Linde: The reason I ask is that I take a prag-
matic approach with psychopharmacology.
I often prescribe antidepressants, particu-
larly bupropion, for the mood component
of methamphetamine withdrawal. If peo-
ple have a history of major depression pre-
dating their methamphetamine abuse, that
will point us toward using antidepressants
more aggressively.
Chang: In those patients, you might expect
overlapping brain imaging patterns.
Linde: However, we still go ahead with
bupropion sometimes where it is unclear or
even unlikely that there is independent
depression. What occurred to me reading
the article is that there might be support for
RESPONSE:  IMAGES AND INTERVENTIONS
Linda Chang, M.D., and Paul Linde, M.D.18 • SCIENCE & PRACTICE PERSPECTIVES—APRIL 2007
this in the imaging studies on dopamine and
the pleasure pathway. If dopamine surges
are responsible for the drug rush and dopamine
is depleted when people become depressed
in withdrawal, doesn’t that suggest that a
dopamine-replenishing medication like
bupropion might help? I’m relatively aggres-
sive, too, about prescribing dextroamphet-
amine or methylphenidate when patients
have really severe low energy and anhedo-
nia and literally can’t get out of bed.
Chang: How soon after they start treatment
are they behaving that way? A long time, or
just during the early months?
Linde:  Some of them, I would say, through
the first 3 months.
Chang: Then do you stop the treatment
after that?
Linde:  Well, I’m still on the front end of
this curve. I’ve only been doing this for about
6 months. When I talk to patients about it,
the vast majority say, “How long do I have
to stay on this? I really don’t want to be on
it long-term.” What I’ve been saying is that
once their recovery is more secure, in the
range of 6 to 12 months, we will look at
tapering them off.
Chang: Are you concerned that they might
become dependent on these medications?
Linde: That’s a good question. It is a risk. I
know I am putting myself out on a limb a
little bit in prescribing psychostimulants to
these patients. I feel okay about it because
the stakes are so high for these individuals.
You’ve got a guy who is a lawyer who has
lost pretty much everything. Yes, there is a
small risk that he will get a new addiction,
but, if he does, it will come from a pre-
scription pad and be legal. He doesn’t use
needles; he doesn’t share needles.
Chang: You’re using the same paradigm as
treating heroin addicts with methadone.
Linde: Yes. The article made me think I may
not be as far out on a limb as I thought. The
imaging studies show that a drug’s abus-
ability is linked to the rapidity and inten-
sity of the dopamine spike it produces.
I’m using oral dextroamphetamine and
methylphenidate, which act more slowly
and steadily than snorted or injected metham-
phetamine or cocaine.
I don’t do this routinely, but there is a
group of patients—professionals, people
with advanced degrees, who are not func-
tioning, but have a relatively good progno-
sis because of their high cognitive baseline
and strong motivation to get back to having
a regular job. I’ve seen some actually do that. 
Chang: The studies you mention on the
role of dopamine in addiction are among
the best examples of the power of neu-
roimaging. Nora Volkow and her colleagues
showed that the high a drug produces is pro-
portional to the dopamine spike it causes in
the brain’s pleasure center, then went on
to show that the rapidity of the response also
determines the high. Cocaine and metham-
phetamine, for example, cause extremely
rapid and intense dopamine surges in the
brain and are addictive. Nicotine, too—in
fact, all drugs of abuse.
Those were fundamental insights into
why people react to drugs the way they
do. The studies also illustrate how learning
about mechanisms can help guide treatment.
They suggest that the same substitution 
therapy that uses methadone or buprenor-
phine to help heroin addicts recover might
work for those abusing other drugs too.
Linde:  At the same time, from my reading,
the findings on substitution therapy for stim-
ulant addiction seem to have been modest
so far. I have the impression that the oral
dextroamphetamine has provided clearcut
benefit only in patients with combined opi-
ate and stimulant addiction who are already
enrolled in a methadone program.
Chang: The odds that we will find a sub-
stitution that works are good, as imaging is
telling us more every day about the neuro-
chemical systems that are involved with
drugs. Slow-release methylphenidate is one
of the more promising possibilities. It is cur-
rently being studied for use in adolescent
drug abusers in the Clinical Trials Network.
Methylphenidate binds to the same dopa-
mine transporters as stimulants like cocaine
and methamphetamine, but it doesn’t cause
the strong and fast dopamine surge that
cocaine or methamphetamine does. It may
turn out to be a good treatment, but it would
be premature to use it now, because safety
studies haven’t been done yet.
Linde: I was very interested in the article’s
mention of GABA enhancers as potential
treatment medications. Can you say more
about that?
Chang: GABA’s role in addiction and
GABA-ergic medication strategies are emerg-
ing research areas. Dr. Stephen Dewey has
been trying to use vigabatrin, or GVG,
to enhance GABA function in cocaine and
nicotine abusers. This works because GABA
modulates release of other neurotransmit-
ters, including dopamine and serotonin.
Based on preclinical work with animals and
some early clinical work, Dr. Dewey’s group
thinks it has great promise for treating
addictions.
One important potential use of imag-
ing in this area is to measure whether these
patients’ GABA levels normalize after GABA-
ergic treatment. Researchers already have
used magnetic resonance spectroscopy to
do this in patients with epilepsy. Dr. Ognen
Petroff at Yale and colleagues have shown
that anticonvulsant treatment with topi-
ramate and other anticonvulsants increases
brain GABA levels.
Linde: I’ve had some success in using a small
amount of clonazepam to help patients come
down from stimulants. Is it possible that
benzodiazepines might do the same bene-
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trin would do—that is, help restore GABA
function?
Chang: Wouldn’t you worry about their
sedative and potential addictive effects?
Linde: I do take those things into account.
If a patient abuses a stimulant and also drinks
a lot or smokes much marijuana, I won’t give
him a benzodiazepine. But there is a small
group of patients who are strictly stimulant
abusers and don’t like anything that makes
them feel down. There also are some patients,
interestingly, whose relapse is triggered by
anxiety rather than depression. Maybe they
are a subset that has attention deficit hyper-
activity disorder. In these groups, I feel
relatively safe using clonazepam—even
though, ordinarily, the benzodiazepines are
the last medications in the world I would
want to give someone who already is hav-
ing problems thinking clearly.
Anyway, when I read what your article
said about GABA, I wondered whether clon-
azepam, for example, may be working on
more than just patients’ anxiety. Maybe its
GABA enhancement has a specific helpful
effect on the stimulant-related brain abnor-
malities.
Chang: That’s a good thought. I haven’t
seen any studies of GABA levels in the brain
in stimulant abusers, but they need to be
done. We should document whether these
levels are abnormal and whether treatment
would improve them.
Linde: In any case, you are going to have
providers who are open to pushing the enve-
lope a little in the use of medications.
Chang: Right. That’s why NIDA is work-
ing really hard to test all the different drugs
through the Clinical Trials Network.
State of the art
Linde: There is a clinic in our area that uses
brain scans along with psychological tests
to assess substance abusers and suggest recov-
ery strategies. On a couple of occasions,
patients have asked me what I think of this,
and I’ve said, “You can go and get the infor-
mation, and then shake a little salt on it.”
Chang: I get contacted by forensic psy-
chologists who are working on legal cases,
asking exactly this kind of question. I tell
them that you can’t be confident, just look-
ing at results from one individual, that you
know how to interpret them. You can’t per-
form imaging in one defendant and con-
clude that, for example, methamphetamine
did or didn’t cause him or her to commit
murder or a violent act.
So far as drug abuse is concerned, imag-
ing is still strictly a research tool, to learn what
drugs do to the brain. The reason has to do
with the size of the signal changes that occur.
They are relatively subtle. If someone has a
stroke or a brain tumor or aneurysm, those
are big signal changes that you can see easily,
and in those cases we use imaging as we use
x-rays, for diagnosis and assessment. Someone
who has been using alcohol for many years
may develop brain atrophy, loss of brain vol-
ume, and you can see the difference with your
naked eye. But the kind of atrophy we see
with stimulant use—you can’t always see it.
Instead, you have to measure the volume with
very sophisticated computer software. It’s the
same with the structural and chemical changes.
The signal changes associated with drug abuse
are so small, in fact, that we have to look at
large groups of subjects and average out the
results to distinguish those that are signifi-
cant from the random background noise pro-
duced by the machine, differences between
individuals, and even single individuals’ day-
to-day variations.
Linde: The concept that science might pin-
point something abnormal in a person’s brain
that would directly indicate how to treat it
is very appealing, though, for both doc-
tors and patients. For example, “Aha, your
amygdala is lacking serotonin. We’ll give
you x to put it right!”—and x may be a med-
ication that’s already on the market for some
other indication.
Chang: That is the hope, of course. The
machines have improved a lot over the last
decade or so because of advances in com-
puter technology and new methods devel-
oped by physicists. We’re getting more pre-
cise measurements, higher sensitivity, better
signals. With continued improvement, we
may get there. But we’re not there yet; at
least that’s my opinion.
Linde: Your paper mentioned that imaging
had implicated genetic variation in trans-
porter activity in vulnerability to drug abuse.
Is there a potential for some day using gene
therapy with this population?
Chang: I think so. The combination of genes,
genetic markers, and imaging can tell us
something about who is at risk and who
might respond to an addictive drug in a cer-
tain way. So, theoretically, that could lead to
early targeted interventions or gene therapy.
We say drug abuse is a brain disease.
Well, that’s right, but it is such a complex
disease. Genetic, environmental, and social
factors also affect the brain, not only drugs
and medications. Imaging may eventually
help us sort out those effects as well. &
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